STERIS plc Annual Report - How They Did This Year

I’ve put together this guide to help you understand how STERIS performed this year. Instead of digging through hundreds of pages of financial filings, I’ve broken down the key takeaways in plain English.

1. What does this company do?

STERIS is a major player in the healthcare industry, providing sterilization, cleaning, and decontamination services to keep medical and surgical equipment safe. They operate in three main areas:

• Healthcare: Provides infection prevention supplies, equipment, and maintenance for hospitals and surgery centers.
• Applied Sterilization Technologies (AST): A global network that sterilizes medical devices and pharmaceuticals for other manufacturers.
• Life Sciences: Supports labs and drug makers with specialized cleaning systems, detergents, and protective products.

Their business model relies heavily on services, which creates "sticky" customer relationships. A large portion of their revenue comes from recurring sales of supplies and service contracts. This provides a stable financial base that balances out the ups and downs of selling expensive equipment.

2. Financial Performance (Fiscal Year Ending March 31, 2026)

STERIS grew its revenue and improved its operational efficiency this year.

• Total Revenue: They brought in $5.94 billion, up 8.7% from $5.46 billion last year.
• Profit: Gross profit reached $2.63 billion, a 9.3% increase. Their profit margin rose to 44.2% from 44.0%, thanks to smart pricing and efficient operations.
• Cash Flow: Cash from operations hit $1.34 billion, up 16.8%. Free cash flow reached $982.9 million, up from $787.2 million. This provides significant capital to reinvest or return to shareholders.
• Debt Load: The company maintains a healthy balance sheet, with a debt-to-total capital ratio of 21.3%, down from 23.6% last year.

3. Shareholder Returns

STERIS returns cash to shareholders through dividends and stock buybacks:

• Dividends: They paid $241.8 million in dividends, or $2.46 per share, up from $2.23 per share last year.
• Buybacks: They spent $225 million to buy back shares. The Board also authorized a new $1 billion buyback program, reflecting management’s confidence in future cash flow.

4. Major Wins and Challenges

• Strategic Cleanup: STERIS is selling its Dental segment to focus on its more profitable core healthcare and sterilization businesses.
• Acquisitions & Investments: They spent $20.1 million on "tuck-in" acquisitions to improve service capabilities and invested $134 million in a non-U.S. healthcare manufacturer to expand their global reach.
• Efficiency: While higher labor and tariff costs presented challenges, the company successfully offset these by raising prices and increasing sales volume across core segments.

5. Financial Health and Risks

STERIS operates a complex global business, supported by strong cash flow that helps buffer against market volatility. Investors should consider the following factors:

• The "EO" Problem: Ethylene Oxide (EO) is a standard sterilization agent. The company faces legal settlements and evolving environmental regulations that could limit EO use or increase operational costs.
• Cybersecurity: As a digitally integrated company, a successful cyberattack could result in fines, legal action, or operational shutdowns.
• Acquisition Risks: Growth is driven by buying other businesses, which carries risks related to integration, potential overpayment, or failing to realize expected synergies.
• Tax Uncertainty: As an Irish company with significant U.S. operations, they are subject to complex tax structures; changes in international tax laws could impact their bottom line.

6. Future Outlook

STERIS is prioritizing its most profitable segments to ensure long-term stability. They expect an aging global population to drive sustained demand for medical procedures, which supports their growth strategy. With a new $1 billion buyback program and consistent cash generation, the company is positioned to balance shareholder returns with the need to manage inflationary and regulatory pressures.

Investor Takeaway: STERIS is a service-heavy, cash-generative business that benefits from recurring revenue. When evaluating this as an investment, weigh their strong balance sheet and commitment to shareholder returns against the specific regulatory risks associated with their sterilization methods and their reliance on a strategy of ongoing acquisitions.